Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

被引：0
|
作者：
T M Beer
D C Smith
A Hussain
M Alonso
J Wang
M Giurescu
K Roth
Y Wang
机构：
[1] Knight Cancer Institute,
[2] Oregon Health & Science University,undefined
[3] University of Michigan Health System,undefined
[4] University of Maryland Medical Center,undefined
[5] Marlene and Stewart Greenebaum Cancer Center,undefined
[6] Private Hospital of Córdoba,undefined
[7] University of Nebraska Medical Center,undefined
[8] Bayer HealthCare Pharmaceuticals,undefined
[9] Astellas Pharma Global Development,undefined
来源：
British Journal of Cancer | 2012年 / 107卷
关键词：
clinical trial; phase II; epothilones; prednisone; prostatic neoplasms;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：808 / 813
页数：5
相关论文
共 50 条
  • [21] A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
    Sridhar, Srikala S.
    Winquist, Eric
    Eisen, Andrea
    Hotte, Sebastien J.
    McWhirter, Elaine
    Tannock, Ian F.
    Mukherjee, Som D.
    Wang, Lisa
    Blattler, Chantale
    Wright, John J.
    Moore, Malcolm J.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1045 - 1049
  • [22] Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer
    Di Lorenzo, Giuseppe
    Buonerba, Carlo
    Faiella, Adriana
    Rescigno, Pasquale
    Rizzo, Mimma
    Autorino, Riccardo
    Perdona, Sisto
    Riccardi, Nando
    Scagliorini, Sarah
    Scognamiglio, Florinda
    Masala, Daniele
    Ferro, Matteo
    Palmieri, Giovannella
    Aieta, Michele
    Marinelli, Alfredo
    Altieri, Vincenzo
    De Placido, Sabino
    Carteni, Giacomo
    BJU INTERNATIONAL, 2011, 107 (02) : 234 - 239
  • [23] Single Agent Vinflunine in the Salvage Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Trial of the Sarah Cannon Research Consortium
    Hainsworth, John D.
    Meluch, Anthony A.
    Lane, Cassie M.
    Spigel, David R.
    Burris, Howard A., III
    Gandhi, Jitendra G.
    Crane, Edward J.
    Stipanov, Michael A.
    Greco, F. Anthony
    CANCER INVESTIGATION, 2010, 28 (03) : 275 - 279
  • [24] PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium
    Pei, Xinqi
    Wu, Kaijie
    Sun, Yinghao
    Xu Gao
    Gou, Xin
    Xu, Jun
    Gao, Fan
    He, Dalin
    Li, Lei
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (01) : 2.e11 - 2.e17
  • [25] Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    Jain, Lokesh
    Gulley, James L.
    Arlen, Philip M.
    Wright, John J.
    Steinberg, Seth M.
    Draper, David
    Venitz, Juergen
    Jones, Elizabeth
    Chen, Clara C.
    Figg, William D.
    Dahut, William L.
    BJU INTERNATIONAL, 2009, 103 (12) : 1636 - 1640
  • [26] Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
    Sternberg, C. N.
    Dumez, H.
    Van Poppel, H.
    Skoneczna, I.
    Sella, A.
    Daugaard, G.
    Gil, T.
    Graham, J.
    Carpentier, P.
    Calabro, F.
    Collette, L.
    Lacombe, D.
    ANNALS OF ONCOLOGY, 2009, 20 (07) : 1264 - 1269
  • [27] A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
    Graff, Julie N.
    Beer, Tomasz M.
    Alumkal, Joshi J.
    Slottke, Rachel E.
    Redmond, William L.
    Thomas, George, V
    Thompson, Reid F.
    Wood, Mary A.
    Koguchi, Yoshinobu
    Chen, Yiyi
    Latour, Emile
    Bergan, Raymond C.
    Drake, Charles G.
    Moran, Amy E.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [28] A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer
    Beardsley, Emma K.
    Hotte, Sebastien J.
    North, Scott
    Ellard, Susan L.
    Winquist, Eric
    Kollmannsberger, Christian
    Mukherjee, Som D.
    Chi, Kim N.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1652 - 1659
  • [29] Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer
    Antonarakis, Emmanuel S.
    Heath, Elisabeth I.
    Smith, David C.
    Rathkopf, Dana
    Blackford, Amanda L.
    Danila, Daniel C.
    King, Serina
    Frost, Anja
    Ajiboye, A. Seun
    Zhao, Ming
    Mendonca, Janet
    Kachhap, Sushant K.
    Rudek, Michelle A.
    Carducci, Michael A.
    ONCOLOGIST, 2013, 18 (02) : 163 - 173
  • [30] KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer
    Petrylak, Daniel P.
    Ratta, Raffaele
    Gafanov, Rustem
    Facchini, Gaetano
    Piulats, Josep M.
    Kramer, Gero
    Flaig, Thomas W.
    Chandana, Sreenivasa R.
    Li, Ben
    Burgents, Joseph
    Fizazi, Karim
    FUTURE ONCOLOGY, 2021, 17 (25) : 3291 - 3299
12345